Linzagolix for treating moderate to severe symptoms of uterine fibroids [ID6190]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Linzagolix for treating pain caused by endometriosis ID6357Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids (TA832)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 19 October 2022
Relugolix–estradiol–norethisterone acetate for treating pain associated with endometriosis [ID3982]Status:In development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 22 April 2024Expected publication date: TBC